Eric Ng
Senior Business Reporter at South China Morning Post
Hong Kong-based senior business reporter, South China Morning Post, focusing on energy and metals mining sectors
Articles
-
4 days ago |
scmp.com | Eric Ng
Chinese biotech firm Akeso, whose cancer drug has been hailed as breakthrough for the nation’s pharmaceutical industry, suffered a setback after less favourable clinical data dashed hopes for a quick US regulatory approval. Akeso’s shares fell 11.6 per cent to HK$73.65 in the morning session on Monday. US partner Summit Therapeutics’ Nasdaq-listed shares slumped 30.5 per cent on Friday to US$18.22, the lowest since April 9.
-
5 days ago |
scmp.com | Eric Ng
Competition in the mainland Chinese market for diabetes and weight loss drugs is set to intensify as more than 60 late-stage drug candidates are undergoing clinical trials, according to a recent report. Up to 20 biosimilar or generic copies will vie for market share and add pricing pressure after Denmark-based Novo Nordisk’s semaglutide product loses patent protection in China next year, according to Boston-based global consultancy L.E.K. Consulting.
-
1 week ago |
retailmenot.com | Eric Ng
Father’s day is less than a month away and we have some great gift ideas for dad today including a unique pair of Dyson headphones, a stainless steel case Apple Watch, and much more. Woot! is a fun place to shop for those like to shop bargain bins because you can find some great discounts on some big and lesser name products. Right now you can save up to 70% off select tech goods from Apple, Anker, Dyson, and much more during their Best of Tech Remix sale.
-
1 week ago |
scmp.com | Eric Ng
A potential multibillion-dollar deal unveiled on Friday by CSPC Pharmaceutical Group is the latest in a growing number of agreements by Chinese biotechnology firms to license development rights for innovative medicines to global pharmaceutical firms, according to lawyers advising the companies.
-
1 week ago |
scmp.com | Eric Ng
Hong Kong surgical robot start-up Cornerstone Robotics, which competes with rival products such as the da Vinci Surgical System, aims to raise more than 500 million yuan (US$70 million) later this year to expand sales and develop new products, according to its chief. Since its founding in 2019, the firm had a deliberate strategy to localise parts production, said founder and CEO Samuel Au Kwok-wai.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 1K
- Tweets
- 1K
- DMs Open
- No
Big Chinese pharma can beat Trump’s policies with cost efficiencies: analysts https://t.co/tMsg3hWkpM Explore our updated app & enjoy a 7-day free trial. New users only. Download now: https://t.co/YiYT7dTyQk
Trump’s tariffs, port fees will force shipping firms to adapt: chamber head https://t.co/W5cuukiMEe Explore our updated app & enjoy a 7-day free trial. New users only. Download now: https://t.co/YiYT7dTyQk
Addiction to China’s tungsten is over even if Beijing turns tap back on, miner says https://t.co/bJXqDkDbe5 Explore our updated app & enjoy a 7-day free trial. New users only. Download now: https://t.co/YiYT7dTyQk